Skip to main content

NUEVAS TERAPIAS PARA LA ENFERMEDAD DE AZLHEIMER BASADAS EN DIANAS DE NEUROLIPIDOS

PI20/00153

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOCRUCES BIZKAIA
Execution centre BIOCRUCES HEALTH RESEARCH INSTITUTE (IIS BIOCRUCES)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Synthesis and pharmacological characterization of a novel cannabinoid receptor 1 antagonist

  • Bengoetxea de Tena, Iker
  • Pereira Castelo, Gorka
  • Martínez Gardeazabal, Jonatan
  • Moreno Rodríguez, Marta
  • Manuel, Iván
  • Martínez Fernández, Claudio
  • Vaz Araújo, Belén
  • Gonzalez Ricarte, Javier
  • Álvarez Rodríguez, Maria Rosana
  • Torres Mozas, Angel
  • Peccati, Francesca
  • Jiménez Osés, Gonzalo
  • Rodríguez de Lera, Ángel
  • Rodríguez Puertas, Rafael
The endocannabinoid (eCB) system regulates several brain functions and is implicated in numerous conditions affecting the brain. Thus, the pharmacological blockade of cannabinoid receptors has a therapeutic potential but produces severe psychiatric side effects. Hence, new cannabinoid compounds with different pharmacological profiles are needed to potentially minimize this toxicity. The objective of this study, featuring original chemical insights, pharmacological analysis, and robust computational methods, was to synthesize and characterize a series of novel antagonists/inverse agonists of cannabinoid receptors. To do so, we first synthesized and then screened 11 novel compounds for affinity for cannabinoid receptors. After that, we characterized in depth the pharmacological profile of the most promising one, UVI3502, which showed affinity for two [3H]CP55,940 binding sites (IC50Hi 0.026 ± 0.43 nM and IC50Lo 772 ± 49.40 nM, R2 = 0.59) in the rat cortex. Binding assays performed in membranes overexpressing cannabinoid receptors 1 and 2 (CB1 and CB2) confirmed moderate affinity for both receptor subtypes, about 10-fold higher for the first one, indicating limited receptor subtype specificity. In key brain areas from the rodent brain, which have a much higher CB1 receptor density than CB2, the affinity of UVI3502 was further studied with neuroanatomical specificity by autoradiography. Functional [35S]GTPγS assays demonstrated that UVI3502 behaved as an antagonist of CB1 receptors, blocking the stimulation evoked by the potent cannabinoid receptor agonist CP55,940. The in silico characterization of the binding to the CB1 receptor through molecular docking and molecular dynamics suggests that this activity is explained by the planar and rigid structure of UVI3502, which is optimal for interactions with the inactive state of the receptor. Hence, we synthesized and characterized UVI3502 as a novel antagonist of CB1, making it a new pharmacological tool for the study of the eCB system and for blocking cannabinoid receptors in the central nervous system., Eusko Jaurlaritza | Ref. IT975-16, Eusko Jaurlaritza | Ref. IT1454-22, Instituto de Salud Carlos III | Ref. PI20/00153, Agencia Estatal de Investigación | Ref. PID2021-125946OB-I00, Agencia Estatal de Investigación | Ref. RYC2022-036457-I, Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa | Ref. BIO22/ALZ/010, Euskal Herriko Unibertsitatea
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of neurolipid signaling and specific lipid species in the triple transgenic mouse model of alzheimer's disease

  • González de San Román, Estíbaliz|||0000-0001-5440-2695
  • Llorente Ovejero, Alberto|||0000-0001-8536-197X
  • Martínez Gardeazabal, Jonatan|||0000-0002-0701-9076
  • Moreno-Rodríguez, Marta|||0000-0002-9980-9365
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Manuel, Ivan|||0000-0003-0958-4738
  • Rodríguez-Puertas, Rafael|||0000-0003-4517-5114
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in aging populations. Recently, the regulation of neurolipid-mediated signaling and cerebral lipid species was shown in AD patients. The triple transgenic mouse model (3xTg-AD), harboring βAPPSwe, PS1M146V, and tauP301L transgenes, mimics many critical aspects of AD neuropathology and progressively develops neuropathological markers. Thus, in the present study, 3xTg-AD mice have been used to test the involvement of the neurolipid-based signaling by endocannabinoids (eCB), lysophosphatidic acid (LPA), and sphingosine 1-phosphate (S1P) in relation to the lipid deregulation. [S]GTPγS autoradiography was used in the presence of specific agonists WIN55,212-2, LPA and CYM5442, to measure the activity mediated by CB1, LPA1, and S1P1 Gi/0 coupled receptors, respectively. Consecutive slides were used to analyze the relative intensities of multiple lipid species by MALDI Mass spectrometry imaging (MSI) with microscopic anatomical resolution. The quantitative analysis of the astrocyte population was performed by immunohistochemistry. CB1 receptor activity was decreased in the amygdala and motor cortex of 3xTg-AD mice, but LPA1 activity was increased in the corpus callosum, motor cortex, hippocampal CA1 area, and striatum. Conversely, S1P1 activity was reduced in hippocampal areas. Moreover, the observed modifications on PC, PA, SM, and PI intensities in different brain areas depend on their fatty acid composition, including decrease of polyunsaturated fatty acid (PUFA) phospholipids and increase of species containing saturated fatty acids (SFA). The regulation of some lipid species in specific brain regions together with the modulation of the eCB, LPA, and S1P signaling in 3xTg-AD mice indicate a neuroprotective adaptation to improve neurotransmission, relieve the myelination dysfunction, and to attenuate astrocyte-mediated neuroinflammation. These results could contribute to identify new therapeutic strategies based on the regulation of the lipid signaling in familial AD patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

  • Navarro-Romero, Alba
  • Galera-López, Lorena
  • Ortiz-Romero, Paula|||0000-0002-6378-6763
  • Llorente-Ovejero, Alberto
  • de los Reyes-Ramírez, Lucía
  • Bengoetxea de Tena, Iker
  • Garcia-Elias, Anna|||0000-0002-6609-6119
  • Mas-Stachurska, Aleksandra|||0000-0003-4947-4111
  • Reixachs-Solé, Marina
  • Pastor, Antoni|||0000-0003-3692-0696
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Benito Villabriga, Begoña|||0000-0002-8668-1251
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Rodríguez-Puertas, Rafael|||0000-0003-4517-5114
  • Campuzano, Victoria|||0000-0001-8128-2641
  • Ozaita, Andres|||0000-0002-2239-7403
Williams-Beuren syndrome (WBS) is a rare genetic multisystemic disorder characterized by mild-to-moderate intellectual disability and hypersocial phenotype, while the most life-threatening features are cardiovascular abnormalities. Nowadays, there are no pharmacological treatments to directly ameliorate the main traits of WBS. The endocannabinoid system (ECS), given its relevance for both cognitive and cardiovascular function, could be a potential druggable target in this syndrome. We analyzed the components of the ECS in the complete deletion (CD) mouse model of WBS and assessed the impact of its pharmacological modulation in key phenotypes relevant for WBS. CD mice showed the characteristic hypersociable phenotype with no preference for social novelty and poor short-term object-recognition performance. Brain cannabinoid type-1 receptor (CB1R) in CD male mice showed alterations in density and coupling with no detectable change in main endocannabinoids. Endocannabinoid signaling modulation with subchronic (10 days) JZL184, a selective inhibitor of monoacylglycerol lipase, specifically normalized the social and cognitive phenotype of CD mice. Notably, JZL184 treatment improved cardiovascular function and restored gene expression patterns in cardiac tissue. These results reveal the modulation of the ECS as a promising novel therapeutic approach to improve key phenotypic alterations in WBS. Williams-Beuren syndrome (WBS) is a rare disorder that causes hyper-social behavior, intellectual disability, memory problems, and life-threatening overgrowth of the heart. Behavioral therapies can help improve the cognitive and social aspects of the syndrome and surgery is sometimes used to treat the effects on the heart, although often with limited success. However, there are currently no medications available to treat WBS. The endocannabinoid system - which consists of cannabis-like chemical messengers that bind to specific cannabinoid receptor proteins - has been shown to influence cognitive and social behaviors, as well as certain functions of the heart. This has led scientists to suspect that the endocannabinoid system may play a role in WBS, and drugs modifying this network of chemical messengers could help treat the rare condition. To investigate, Navarro-Romero, Galera-López et al. studied mice which had the same genetic deletion found in patients with WBS. Similar to humans, the male mice displayed hyper-social behaviors, had memory deficits and enlarged hearts. Navarro-Romero, Galera-López et al. found that these mutant mice also had differences in the function of the receptor protein cannabinoid type-1 (CB1). The genetically modified mice were then treated with an experimental drug called JZL184 that blocks the breakdown of endocannabinoids which bind to the CB1 receptor. This normalized the number and function of receptors in the brains of the WBS mice, and reduced their social and memory symptoms. The treatment also restored the animals' heart cells to a more normal size, improved the function of their heart tissue, and led to lower blood pressure. Further experiments revealed that the drug caused the mutant mice to activate many genes in their heart muscle cells to the same level as normal, healthy mice. These findings suggest that JZL184 or other drugs targeting the endocannabinoid system may help ease the symptoms associated with WBS. More studies are needed to test the drug's effectiveness in humans with this syndrome. Furthermore, the dramatic effect JZL184 has on the heart suggests that it might also help treat high blood pressure or conditions that cause the overgrowth of heart cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Handling and novel object recognition modulate fear response and endocannabinoid signaling in nucleus basalis magnocellularis

  • Bengoetxea de Tena, Iker
  • Moreno-Rodríguez, Marta|||0000-0002-9980-9365
  • Llorente-Ovejero, Alberto
  • Monge-Benito, Sergio|||0000-0001-8061-6865
  • Martínez-Gardeazabal, Jonatan
  • Onandia-Hinchado, Iban
  • Manuel, Ivan|||0000-0003-0958-4738
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Rodríguez-Puertas, Rafael|||0000-0003-4517-5114
Storage of aversive memories is of utmost importance for survival, allowing animals to avoid upcoming similar stimuli. However, without reinforcement, the learned avoidance response gradually decreases over time. Although the molecular mechanisms controlling this extinction process are not well known, there is evidence that the endocannabinoid system plays a key role through CB receptor-mediated modulation of cholinergic signaling. In this study, we measured fear extinction throughout 7 months using naïve rats, assessed in passive avoidance (PA) test in a non-reinforced manner. Then, we evaluated the effect of gentle handling and non-aversive novel object recognition test (NORT) on the extinction and expression of fear memories by measuring passive avoidance responses. Neurochemical correlates were analyzed by functional autoradiography for cannabinoid, cholinergic, and dopaminergic receptors. Despite results showing a gradual decrease of passive avoidance response, it did not fully disappear even after 7 months, indicating the robustness of this process. Meanwhile, in rats that received gentle handling or performed NORT after receiving the PA aversive stimulus, extinction occurred within a week. In contrast, gentle handling performed before receiving the aversive stimulus exacerbated fear expression and triggered escape response in PA. The neurochemical analysis showed increased cannabinoid and cholinergic activity in the nucleus basalis magnocellularis (NBM) in rats that had performed only PA, as opposed to rats that received gentle handling before PA. Additionally, a correlation between CB mediated-signaling in the NBM and freezing in PA was found, suggesting that the endocannabinoid system might be responsible for modulating fear response induced by aversive memories.